Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0015672 (fatigue)
 51,768 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Symptomatic fatigue has not been investigated previously in a multiple sclerosis population. Potential subjects were the 78% of 656 individuals with multiple sclerosis who indicated in a previous study that they experienced symptomatic fatigue. Three hundred nine subjects (60%) returned a follow-up questionnaire on symptomatic fatigue. Ninety percent described fatigue as "tiredness or the need to rest," but 43% of them indicated that "sleepiness" was part of the symptomatology. In 48% fatigue made other MS symptoms worse. Fatigue tended to occur in the late afternoon and evening. It occurred almost daily for more than 66% of the subjects. In 47% of the subjects fatigue usually subsided within a few hours; in other subjects occurrences were of variable length (40%) or lasted between 6 and 24 hours (8%). Ninety percent said that fatigue was worse at warmer environmental temperatures. Fatigue was worse for 83% after "vigorous exercise" and for 64% after "moderate exercise" although 15% reported that moderate exercise helped to reduce fatigue. Meditation, some drugs, and cooling with water reduced fatigue in a majority of the small proportion of the population trying these techniques. A planned daily schedule of activity and rest seemed to be a partially effective response to symptomatic fatigue for the majority of subjects studied.
 ...
PMID:Symptomatic fatigue in multiple sclerosis. 670 89

This study quantified the effects of an aquatic exercise program on muscular strength, endurance, work, and power of patients with multiple sclerosis. Ten individuals with a mean age of 40 years participated in a 10-week aquatic exercise program. Two types of isokinetic dynamometers were used to assess the muscular variables studied. A Cybex II dynamometer was used to measure peak torque, work, and fatigue in the knee flexor and extensor muscles and a biokinetic swim bench was used to measure muscular force, work, fatigue, and power in the upper extremities. Five velocity settings were selected for each of three testing trials (pretrial, midtrial, and posttrial). For the lower extremities, analysis of variance indicated a significant improvement of peak torque for knee extensor muscles from the pretrial to midtrial (p less than .05). Peak torque values from pretrial to midtrial for knee flexors and from midtrial to posttrial for both the knee extensor and flexor muscles indicated a nonsignificant difference at each velocity studied. Fatigue and work values in the lower extremities improved significantly between the pretrial and posttrial (p less than .05). For the upper extremities, an analysis of variance indicated a significant increase in all force measurements from pretrial to posttrial (p less than .05). Power and total work values also improved significantly (p less than .05). No significant difference in fatigue measurements for the upper extremities was found. The results of this investigation indicated that an aquatic exercise program may induce positive changes in muscular strength, fatigue, work, and power in patients with multiple sclerosis.
 ...
PMID:Effects of an aquatic fitness program on the muscular strength and endurance of patients with multiple sclerosis. 671 94

The delay between the stimulus and the voluntary eye saccade is the only parameter of the saccadic system which can be measured by using standard apparatus. Taking manually the measurements made on records obtained by using minicomputer; the authors show that such manual measurement of latencies is easy and yet sufficiently accurate to be of great clinical value. The latencies of voluntary saccades are normal in peripheral pathology (less than 250 milliseconds). Latencies of voluntary saccades are significantly increased in extrinsic brain stem lesions: tumours (in particular ponto cerebellar tumours), meningitis, head injury; but the velocity of the saccade is normal. This effect goes in parallel with impairement of the smooth pursuit. In intrinsic brain stem lesions (multiple sclerosis, acute brain stem stroke, oculomotor paralysis) latencies are increased bilaterally and above all, there is a significant slowing of the saccade. The role of fatigue increased latencies in some patients of this series. Two populations can be discerned in vestibular neuritis: one normal and one with abnormal smooth pursuit and increased saccadic latencies.
 ...
PMID:[Measurement of the latencies of voluntary and corrective ocular saccades. Value in otoneurology]. 684 74

A double-blind trial with two parallel groups was carried out to compare the antispastic effect and tolerability of a new muscle relaxant, tizanidine (DS 103-282), with those of baclofen in the treatment of spasticity due to multiple sclerosis. Twenty-one hospitalized patients with stable spasticity participated in the 6-week trial. Eleven received tizanidine and 10 baclofen in gradually increasing daily doses. The optimal daily dose of tizanidine was between 8 and 36 mg and that of baclofen between 10 and 80 mg. Overall spastic state, spasms and clonus were similarly improved with both medications. In contrast, muscle strength, bladder function and the activities of daily living were more improved on tizanidine than on baclofen. Tiredness was the most frequent side-effect on tizanidine and muscle weakness on baclofen. The laboratory tests did not show any pathological changes with either medication. According to these results, tizanidine provides a new therapeutic alternative in the treatment of spasticity.
 ...
PMID:A double-blind comparative trial of new muscle relaxant, tizanidine (DS 103-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis. 701 49

Evaluation of rocker shoes as a walking aid for multiple sclerosis patients included a mechanical analysis of the shoes, establishment of clinical criteria for appropriate patient selection, and laboratory gait measurements of patients with and without rocker shoes. Patient fitting demonstrated that the most significant measurement, the roll point, must be about 2cm proximal to the 1st metatarsal head. A snug fit as well as the addition of a heel strap was required to hold the shoe on the foot so its mechanical assistance was consistent. Rocker shoes were effective only in patients who still retained the ability to walk independently; retention of adequate hip and calf strength proved critical. Basic gait deficit was plantar flexion less than 15 degree while standing, leading to knee hypertension and forward trunk leaning, inadequate knee flexion and toe drag in swing, general awkwardness and fatigue. Gait improvement with the rocker shoes varied with clinical classification. Normal velocity and stride characteristic in rocker shoes were accompanied by a marked decrease in net energy cost. A mean saving of 150% of normal energy was gained with rocker shoes.
 ...
PMID:Rocker shoe as walking aid in multiple sclerosis. 723 87

The retinal ganglion cell exhibits two types of functional change. The difference in response appears to depend on whether or not the retrobulbar portion of the optic nerve is actively involved. This may imply differences in the myelinated and non-myelinated portions of the optic nerve and associated structures. In open angle glaucoma, alterations in the sustained- and transient-like functions but not in the flashing repeat static test are found. That is, there are changes in spatial neural interactions, but there is no evidence of a visual fatigue or saturation-like effect. In optic nerve radiation damage without evidence of retinal vascular changes, in optic neuritis secondary to multiple sclerosis, chiasmal lesions, and ischemic optic neuropathy (considered here) varying degrees of visual fatigue or saturation-like effects are demonstrated with little or no change in the sustained- or transient-like functions.
 ...
PMID:Different functional changes recorded in open angle glaucoma and anterior ischemic optic neuropathy. 747 32

The goals of this study were to investigate muscle fatigue in patients with multiple sclerosis (MS), and to determine the relationships between muscle fatigue, clinical status, and perceived fatigue. The fatigability of the anterior tibial muscle was quantitated in patients and controls during 9 min of intermittent stimulation (used to eliminate central sources of muscle fatigue). During exercise, the decline in tetanic force, phosphocreatine, and intracellular pH was greater in patients than in controls. The compound muscle action potential amplitude did not decrease during exercise, indicating that there was no failure of neuromuscular transmission during fatigue. Thus, the excessive fatigue in MS developed from sources beyond the muscle membrane. Following exercise, the recovery of tetanic force was delayed in patients (a pattern that suggests abnormal excitation-contraction coupling), whereas the recovery of metabolites was complete in both groups. Muscular fatigue was correlated with clinical disability but not with perceived fatigue. These results suggests that fatigue in MS has both central (perception, upper motor neuron dysfunction) and peripheral (impaired metabolism and excitation-contraction coupling) components.
 ...
PMID:Evidence of an abnormal intramuscular component of fatigue in multiple sclerosis. 747 63

Since their initial description in 1957, the interferons (IFNs) have been increasingly used to treat a wide array of diseases. Acute adverse effects, i.e. 'flu-like' syndromes, hypo- or hypertension, tachycardia, headache, myalgias and gastrointestinal disorders, occur within the first hour or day after starting treatment. They are seldom treatment-limiting and are easily manageable. Sub-acute and chronic effects develop after several days, usually within 2 and 4 weeks of therapy. The most typical is neurological toxicity, including fatigue/asthenia, and behavioural and cognitive changes. Such symptoms may seriously impair quality of life and result in treatment discontinuation. Seizures have seldom been described. Other infrequent central nervous system adverse effects include vertigo, cramp and oculomotor nerve paralysis. Distal paraesthesias and peripheral neuropathy have been reported. IFN-associated autoimmunity is quite rare but a matter of concern. Biological or clinical manifestations usually require several months to become apparent. Autoantibodies have been shown to develop in most patients but have been inconsistently associated with clinical symptoms of systemic lupus erythematosus, rheumatoid-like arthritis and thyroiditis. Both hypo- and hyperthyroidism have been described but are usually reversible. Other infrequent autoimmune reactions include diabetes, pemphigus and worsening of multiple sclerosis. Although several patients present with a pre-existing autoimmune disorder, no predisposing factor has been clearly established. While hypotension and tachycardia are the most frequent acute cardiovascular complications, a few additional cases of cardiac arrhythmias and myocardial ischaemia have been reported after a short course or several weeks of treatment. These latter complications do not appear to be dose-dependent or age-related. Isolated cases of congestive heart failure have also been described. Mild proteinuria has been observed in 15 to 25% of patients, but acute renal toxicity is uncommon. A transient rise in serum aminotransferase levels is frequently noted during the first stage of therapy, especially in patients receiving the highest dosages. Direct hepatotoxicity is extremely rare. Autoimmune hepatitis, which is ill-diagnosed as chronic viral hepatitis, and de novo induction of autoimmune hepatitis, account for the majority of liver diseases. Haematotoxicity is relatively common but mild to moderate, and develops gradually during the first weeks of treatment. Neutropenia is the most common haematological toxicity, but is usually not dose-limiting and resolves rapidly upon drug discontinuation. Myelosuppression, autoimmune and immune allergic haemolytic anaemias and thrombocytopenias have seldom been described. Cutaneous adverse effects comprised nonspecific erythema and hair loss and, less frequently, vasculitis, local ulcerations at the site of injection and exacerbation of psoriasis.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Clinical toxicity of the interferons. 751 63

To evaluate the underlying mechanisms of cognitive decline in multiple sclerosis, two clinically and demographically matched multiple sclerosis groups differing in cognitive status were assessed with attention related tasks. In addition to the attention tests recommended by the Cognitive Function Study Group of the American National Multiple Sclerosis Society, a test of sustained attention was used to evaluate the role of possible fatigue on cognitive performance. The cognitively mildly deteriorated group was slower than the cognitively preserved group and the controls on all tests of attention. The mildly deteriorated group did not, however, consistently differ from the other groups in the error scores of the attention tests. The preserved group exhibited slowness at the end of the visual vigilance test, but no deficits were found on the other attention related tests in this group. It is suggested that dissociable kinds of processing slowness are the origin of the deficits found on the attention tests in the two multiple sclerosis groups. Our preserved group exhibited signs of motor and fatigue related slowness, whereas the mildly deteriorated group also had extensive cognitive slowness. As sensitive indicators of cognitive slowness, attentional tests should be included in evaluation of the cognitive status of patients with multiple sclerosis.
 ...
PMID:Attention related performance in two cognitively different subgroups of patients with multiple sclerosis. 760 14

Because amantadine has been shown to reduce fatigue in patients with multiple sclerosis, we performed a double-blind, placebo-controlled study to assess its efficacy in the disabling symptom of post-polio fatigue. Twenty-three patients completed six weeks of therapy. Fatigue was measured by the patients using visual analogue scales (twice per day) and numerical fatigue severity scales (once per week) and by overall impression (at end of therapy). Formal neuropsychological testing and serum drug levels were performed to assess compliance. On all measures, no significant difference was found between treatment and placebo groups. Fifty-four percent of patients given amantadine and 43% given placebo reported a decrease in fatigue; however, the visual analogue scales and fatigue severity scales failed to reflect any improvement. Several patients in the treatment group elected to continue amantadine therapy after the study was completed. Our findings suggest that amantadine is not significantly better than placebo in reducing the sensation of fatigue in post-polio syndrome, and that the measures we employed were insensitive to capture the subjective response experienced by a few patients.
 ...
PMID:A double-blind, placebo-controlled trial of amantadine for the treatment of fatigue in patients with the post-polio syndrome. 761 38


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>